Concerns Diverting Active Stocks Direction: BP p.l.c. (NYSE:BP), Endologix, Inc. (NASDAQ:ELGX)

Shares of BP p.l.c. (NYSE:BP) [Trend Analysis] runs in leading trade, it surging 0.38% to traded at $37.25. The firm has price volatility of 0.67% for a week and 1.14% for a month. Its beta stands at 1.17 times. Shell Midstream Partners L.P. said that it has acquired 10% interest in Proteus Oil Pipeline Company, LLC, 10% interest in Endymion Oil Pipeline Company, LLC, and a 1% interest in Cleopatra Gas Gathering Company, LLC from BP.The acquisition price reflects an approximate 7.7 times multiple of Shell’s forecasted annual average Adjusted EBITDA attributable to the purchased interests over 2017 and 2018. The acquisition is expected to be immediately accretive to unitholders.

Proteus is a 71-mile crude oil pipeline with a 425,000 bpd capacity. The pipeline provides access to the Mississippi Canyon area of the Gulf of Mexico from the Thunder Horse and Thunder Hawk platform to the Proteus SP 89E Platform. Noble Energy’s Big Bend and Dantzler fields are tied back to the Thunder Hawk platform. Narrow down four to firm performance, its weekly performance was 2.00% and monthly performance was 10.47%. The stock price of BP is moving up from its 20 days moving average with 3.30% and isolated positively from 50 days moving average with 6.53%.

Several matter pinch shares of Endologix, Inc. (NASDAQ:ELGX) [Trend Analysis], as shares surging 1.14% to $5.33 with a share volume of 8.07 Million. Khang&Khang LLP reported that it is investigating claims against Endologix, Inc. (ELGX) concerning possible violations of federal securities laws.Nellix is Endologix’s endovascular aneurysm sealing system used against infrarenal abdominal aortic aneurysms.

Endologix allowed the Nellix system to be applied in the Nellix investigational device exemption (IDE) clinical trial, the EVAS FORWARD-IDE Study. However, Endologix revealed that the FDA asked for a follow-up on patients in the EVAS-FORWARD-IDE study to measure Nellix. On December 27, 2016 Endologix revealed that it was barring AFX Endovascular AAA System shipments indefinitely because of a manufacturing investigation. The stock is going forward its 52-week low with 1.33% and moving down from its 52-week high price with -63.24%. To have technical analysis views, liquidity ratio of a company was calculated 2.50 as evaluated with its debt to equity ratio of 1.31. The float short ratio was 20.33%, as compared to sentiment indicator; Short Ratio was 9.55.


About Blake Escott

Blake Escott holds junior writer position in SWR. Before joining Streetwise Report, he was a freelance content Writer. He has high-level copywriting experience and particularly experienced in proofreading and editing. He covers news about different companies including all US market sectors. Interests: Commodities, Energy stocks, Sector-wise Stocks analysis, Utilities

Leave a Reply

Your email address will not be published. Required fields are marked *